Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | SNCA | P37840 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | APEX1 | P27695 | 3/20 | 0.71 |
| ▸ | RECQL | P46063 | 3/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | RAD52 | P43351 | 2/20 | 0.71 |
| ▸ | CNR1 | P21554 | 1/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13099977 | 1.00 | BACE1 (0.71) | BACE1PTGS1KDM4ESNCAALDH1A1 | |
| SCHEMBL862117 | 0.89 | BACE1 (0.63) | BACE1PTGS1KDM4ESNCAALDH1A1 | |
| SCHEMBL26481134 | 0.89 | BACE1 (0.59) | BACE1PTGS1KDM4ESNCAALDH1A1 | |
| SCHEMBL21586653 | 0.89 | ABCB1 (0.76) | BACE1PTGS1KDM4ESNCAALDH1A1 | |
| SCHEMBL13099973 | 0.89 | BACE1 (0.78) | BACE1PTGS1KDM4ESNCAALDH1A1 | |
| SCHEMBL13099978 | 0.88 | KDM4E (0.73) | BACE1PTGS1KDM4ESNCAALDH1A1 | |
| SCHEMBL862191 | 0.88 | KDM4E (0.73) | BACE1PTGS1KDM4ESNCAALDH1A1 | |
| SCHEMBL862110 | 0.85 | BACE1 (0.62) | BACE1PTGS1KDM4ESNCAALDH1A1 | |
| SCHEMBL1974812 | 0.85 | BACE1 (0.62) | BACE1PTGS1KDM4ESNCAALDH1A1 | |
| Epigallocatechin SCHEMBL1972938 | 0.84 | BACE1 (1.00) | BACE1PTGS1KDM4ESNCAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| CN-110183431-B | Compound for treating or preventing liver diseases | 江苏新元素医药科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2021-08-12 | — | — | US | disclosed |
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2021-08-12 | — | — | US | disclosed |
| EP-3805216-A1 | COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805216-A1 | COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019233440-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | 江苏新元素医药科技有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019233440-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | 江苏新元素医药科技有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | SLC10A1, GYS2, CPT1A | BACE1 1906/4885PTGS1 342/4885KDM4E 4649/4885 |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | SLC10A1, GYS2, CPT1A | BACE1 1906/4885PTGS1 342/4885KDM4E 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.